CytoDyn (CytoDyn) COGS-to-Revenue

: 0.00 (As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

CytoDyn's Cost of Goods Sold for the three months ended in Feb. 2024 was $0.00 Mil. Its Revenue for the three months ended in Feb. 2024 was $0.00 Mil.

CytoDyn's COGS to Revenue for the three months ended in Feb. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CytoDyn's Gross Margin % for the three months ended in Feb. 2024 was N/A%.

CytoDyn COGS-to-Revenue Historical Data

The historical data trend for CytoDyn's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

COGS-to-Revenue

276.48

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
COGS-to-Revenue																-	-	-	-	-

CytoDyn COGS-to-Revenue Calculation

CytoDyn's COGS to Revenue for the fiscal year that ended in May. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	20.633	/	0
	=

CytoDyn's COGS to Revenue for the quarter that ended in Feb. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

CytoDyn (OTCPK:CYDY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CytoDyn's Gross Margin % for the three months ended in Feb. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CytoDyn COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CytoDyn's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660